Introduction
An artificial pancreas (AP) is an automatic device for regulating glucose in diabetes patients. A new perspective for the development of a device suitable for outpatient use started with the availability of subcutaneous (SC) glucose sensors and SC insulin pumps. The integration of these two components with a control algorithm is called the AP. In particular, in 1999, MiniMed introduced a commercial continuous glucose monitoring (CGM) system. Since then, several research projects studied and experimented with AP systems, starting with the MiniMed AP project, 1 with an acceleration caused by the launch of research projects funded by the JDRF, the European Commission, and the National Institutes of Health. [2] [3] [4] [5] [6] Designing a control algorithm for the SC-to-SC glucose-insulin system is challenging, because the system is characterized by significant interindividual variability, time-varying dynamics, nonlinear phenomena, and time delays due to the absorption of insulin from the SC level to the blood and, in reverse, of glucose from the blood to the SC level. Moreover, the glucose profile depends on the insulin, whose delivery is bounded not only within an interval ranging from zero to a maximal value imposed by the pump, but also on very important disturbances such as meals and physical exercise that may be predicted to some extent.
The objective of the control algorithm is to keep the glucose levels within an optimal range (70-140 mg/dl). In the literature, several algorithms have been presented starting from proportional-integral-derivative schemes 1, 7 and, more recently, relying on a very promising approach called model predictive control (MPC). 2, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] So far, encouraging pilot results have been reported using proportional-integral-derivative control 1, 3 and MPC strategies. 4, 6, 19 In Breton and coauthors, 20 the MPC algorithm described by Patek and coauthors 18 was in vivo tested. A comparison of two MPCbased artificial pancreas systems was performed by Luijf and coauthors. 21 The study was performed on 48 patients with type 1 diabetes and consisted of three randomized 24 h admissions (with 23 h of closed-loop control in two of the admissions and one control admission with open loop) to the clinical research center. One of the closed-loop controls is the iAP (or International Artificial Pancreas Study Group) control algorithm, developed following the modular architecture proposed by Patek and coauthors 18 that includes the MPC algorithm described by Soru and coauthors, 10 herein called MPC1, and the safety supervision module (SSM) described by Hughes and coauthors. 22 In this article, a new MPC version, herein called MPC2, was designed based on collected data and other clinical experiences. The results illustrated in this article were tested in silico using the simulator developed by the Universities of Padova and Virginia equipped with a new cohort of virtual subjects that span sufficiently well the interindividual variability of key metabolic parameters in the general population of diabetes patients (see the work of Dalla Man and coauthors 23 ).
Methods
The MPC1 algorithm takes advantage of the knowledge of conventional therapy that addresses glucose regulation by a mix of piecewise constant insulin infusion, also called basal insulin, u b , and impulse-like injections that are made just before meals to prevent excessive rises of blood glucose (BG), also called insulin bolus, u bolus . In the absence of meals, the basal insulin, which varies from patient to patient, would eventually bring BG to a steady-state value, called basal glucose, G b . The amount of the insulin bolus is scaled to the meal size using the patient parameters carbohydrate-toinsulin ratio and correction factor.
MPC1 is the linear model predictive control (LMPC) described by Soru and coauthors 10 that uses an approximate linear model of the insulin-glucose dynamics obtained from the linearization around a suitable working point of the more complex nonlinear model reported in by Magni and coauthors. 9 The derived linearized model can be written in the following form: where x(k) ∈ R 13 is the state as reported in Table 1 , y(k) = CGM(k) -G b (mg/dl) is the difference between the SC glucose and the basal value (G b ), u(k) = i(k)u b (k) (pmol/kg) is the difference between the injected insulin and its reference value (normalized by the patient weight), and d(k) (mg) represents the meal.
Thereafter, it is assumed that the triplet (A, B, C) is both stabilizable and detectable. The LMPC algorithm uses this model to predict the future glucose profile given the carbohydrates and insulin taken in by the patient.
The cost function is a quadratic penalty defined as
where q is the positive scalar weight and N is the prediction
where P is the unique nonnegative solution of the discrete time Riccati equation:
The reference signals are defined as y o (k) = ñ y(k) -G b (mg/dl), the difference between the reference value (ñ y) of the SC glucose and the glucose basal value (G b ), and u o (t) = ũ(k)u b (k) (pmol/kg), the difference between the reference value (ũ) of the insulin profile and the insulin basal value (u b ), normalized by the patient weight.
The control law associated with a constrained LMPC may be derived either by solving an on-line quadratic programming problem or through a multiparametric approach, whose result is a piecewise constant control law that can be computed offline.
However, in view of the restrictive regulatory constraint and the significant uncertainty in the model, and in order to avoid online optimization or the computational and memory burdens of an explicit MPC for constrained systems, the proposed algorithm does not include explicit constraints. Hence it is possible to calculate the closed-form solution:
where K x ∈ R Nx13 , K d ∈ R NxN , K Yo ∈ R NxN , K Uo ∈ R NxN are derived as described in by Soru and coauthors 10 and
is the vector of future meals and
In general, the state x(k) of the model is not accessible, so a Kalman filter is used to estimate it. The Kalman filter improves the quality of the information provided to the LMPC algorithm, exploiting the knowledge included in the model as well as the past injected insulin. In fact, the Kalman filter is used to update the estimated glucose-insulin state using past information about glucose, insulin, and carbohydrates. The linear system (Equation 1), affected by noises, is written as
and the initial state x 0 = x(0) is assumed to be a zero mean Gaussian random variable independent of v.
From clinical data collected during the Comparison of Two Artificial Pancreas Systems for Closed-Loop Blood Glucose Control versus Open-Loop Control in Patients with Type 1 Diabetes (CAT) AP@home trial reported by Luijf and coauthors, 21 three major problems were pointed out: a measurement error larger than the one assumed for Kalman filter tuning, a virtual population used for controller synthesis whose insulin sensitivity was underestimated, and toohigh nocturnal glucose levels.
New Measurement Error Model Derived from CAT AP@home
From the 141 data sets relative to the 47 patients enrolled in the CAT AP@home trial, information about BG and CGM was extracted. The BG sampling time was 15 min, with exception of the evening hours when it was decreased to 30 min and the night when it was 60 min. The CGM was sampled with the Dexcom Seven ® Plus every 5 min. A critical point in the synthesis of a closed-loop controller is the quality of the measurement error model. The University of Virginia/Padova simulator, 24 used to tune the MPC by Soru and coauthors, 10 includes the error model proposed by Breton and Kovatchev 25 consisting of an autoregressive [AR(1)] model and a nonlinear Johnson function. In order to evaluate the capability of the measurement error model to describe the real difference between SC glucose concentration and CGM, the scheme reported in Figure 1 is first introduced. The relation between BG and interstitial glucose is modeled as a first-order system with time constant t, which is representative of the lag between the blood and SC glucose concentrations. As constant t is unknown and patient dependent, a sensitivity analysis of ê with respect to t is made by considering the latter as a lognormal stochastic variable with mean 10.27 [s] and variance 7.18 [s 2 ]. The estimate of the measurement error ê is compared with the modeled error ê M through the visual predictive check approach. 26 The visual predictive check representation of ê and ê M obtained through the model proposed by Breton and Kovatchev, 25 reported in Figure 2A , shows that the variability of the measurement error is significantly underestimated. Some limitations of this model error are already pointed out by Facchinetti and coauthors, 27 and thanks to the availability of four simultaneous sensor data, a new description of the components of the sensor model error has been proposed by Facchinetti and coauthors. 28 Here a new autoregressive [AR(2)] model is identified in order to describe the total measurement error, including wearing issues in addition to noise and drift usually considered. The new model can be described by
where error v(k) is a Gaussian white noise with mean m v and variance s 2 v, parameters a 1 and a 2 are coefficients of the autoregressive model, and the distribution of the initial states of the process is normal with mean m is and variance s 2 is (see Table 2 ).
The results obtained with the new model are presented in Figure 2B . Also, the mean absolute relative difference (MARD) 29 between CGM and BG obtained with the model (median 15%, interquartile range 13-17%) is in agreement with the data collected during the CAT AP@ home trial (median 12%, interquartile range 10-18%); it is also similar to the MARD obtained with the Dexcom Seven Plus by Christiansen and coauthors 29 (median 14%, interquartile range 12-20%). In order to use this model with other sensors, variance s 2 v must be adapted. For example, with s 2 v = 0.0141, the MARD is 11% with interquartile range 10-13%, similar to that of the Dexcom G4 (median 12.5%, interquartile range 9-16%) reported by Christiansen and coauthors. 29 
Model Predictive Control Retuning
The MPC algorithm was improved by exploiting the experience gained with the AP@home experiments. The main changes in the MPC2 algorithm are listed and described as follows: Here it is adapted considering also the patient's BG concentration at the time of meal acknowledgement. Specifically, the correction, which is limited to percentage m of the nominal meal bolus value, is computed as
where y target is the glucose reference and m is the maximum allowed meal bolus correction.
Meal Bolus Limitation
A limitation on the maximum bolus deliverable for each meal is also introduced: a maximal a% of the nominal bolus can be suggested to compensate for the meal. In formal terms, Equation (3) was modified as
Insulin Constraint
Due to the unconstrained nature of the MPC1, the finite horizon optimal solution can include negative insulin suggestions that obviously cannot be applied in the future. Hence the following constraint was introduced:
where N i is the considered horizon. This formula limits the suggested insulin, allowing also the possibility to suggest at least a percentage b of the basal in the future. In order to limit the MPC action, the control variable was also saturated according to the following rule:
where i is the insulin effectively injected in the past and N v is the considered horizon.
Pump Shutoff Avoidance
In the literature, it is widely documented that the absence of insulin delivery for a long period can lead to metabolic decompensation and diabetic ketoacidosis. 30 However, short-interval interruption of basal insulin infusion may also result in risks of ketosis. 31 In order to avoid these events, a new constraint was added:
where g is the guaranteed fraction of basal delivery in the future and Ḡ is a switching threshold.
Insulin Variation Constraint
Finally, data analysis showed that spikes in CGM can cause excessive reaction of the control algorithm. Hence, in order to avoid an increase of the suggested insulin greater than ζu b , the MPC suggestion was corrected as
Meal boluses can violate this constraint.
Retuning of the Cost Function Using a New Virtual Population of Patients and the New Sensor Noise Model
Glucose profiles observed in the AP@home trials exhibited a relatively high glucose average (148.21 ± 20.42); therefore the glucose set point (ñ y) was decreased. Moreover, the prediction horizon was shortened for embedded implementation. 32 This is possible without performance degradation in view of the terminal penalty in Equation (2) that approximates the infinite horizon cost. Finally, the cost function was retuned following the procedure described by Soru and coauthors 10 using the new virtual population 23 and the sensor model described in this work.
Kalman Filter Retuning
In order to improve the predictions of the Kalman filter, a retuning of the Q KF and R KF matrices, exploiting both the AP@home data and the new sensor error model, was implemented. Q KF was set as a diagonal matrix whose entries q i are gathered in five homogeneous groups taking the same values (see Table 3 ). Noise covariance matrix R KF was set equal to the variance of signal v(k) (described in this article) while process noise covariance matrix Q KF was tuned by minimizing the sum of the prediction error defined as
where I p is the measured plasma insulin, Î p is the plasma insulin estimated by the Kalman filter, BG is the measured plasma glucose, BG is the plasma glucose estimated by the Kalman filter, and h is a suitable weight. The optimization was performed by an exhaustive research over a grid that considered for each q i , three possible values: 0.1, 1, and 10. The optimal values are reported in the last column of Table 3 .
Results and Discussion
This section reports the in silico comparison between the MPC1 algorithm, used in the CAT AP@home trial, 10 where the coefficients were computed through the procedure described by Soru and coauthors 10 applied to 50 virtual patients.
Three different scenarios were evaluated: a nominal one in which all parameters were known, a sensitivity variation scenario where a ±25% variation was randomly applied to the insulin sensitivity of each in silico patient in order to represent possible uncertainty on individual insulin sensitivity, and a meal variation scenario where the ingested amount of carbohydrates is the nominal one multiplied by a random factor uniformly distributed in [0.5 1.5] in order to reproduce a possible error in meal amount calculation. Each simulation started at 06:00 and lasted 34 h. Five meals were administrated during the whole trial: breakfast at 07:00 (50 g), lunch at 12:00 (60g), dinner at 18:30 (80g), and second breakfast and second lunch equal to the previous. In all scenarios, four sensor calibrations were planned per day: 30 min before each meal (06:30, 11:30, and 18:00) and one before the night (23:00). The comparison reported here was performed with the new virtual population 22 composed of 100 adult patients and the sensor noise model presented in this work.
Differences in outcomes measures is assessed according with data distribution as reported in Table 4 . Figure 3 shows the results in terms of glucose profiles obtained with both algorithms in the nominal scenario: the glucose mean with MPC2 tends to the set point in the nocturnal period; moreover, lower excursions in the postprandial periods that cause hypoglycemia phenomena with MPC1 are reduced. MPC1 acts too aggressively after meals and maintains a high glucose level during the night. Figure 4 shows the improvement obtained with the new algorithm on an improved version of the classic control variability grid analysis (CVGA). 36 This improved version was introduced Soru and coauthors 10 by allowing the classic CVGA nine square zones, associated with different control performance, to become concentric rings zones ranging from A to D. Axis scales and hence subject position remain the same. This new CVGA removes the limitation that a patient could move to a better zone with a slight reduction of one of the coordinates even at the The same considerations can be deduced from the analysis of the glucose profile obtained with the sensitivity variation scenario (see Figure 5 ) and the meals variation scenario (see Figure 6 ). From the CVGA representation with the sensitivity variation scenario (Figure 7) , it is apparent that the MPC2 reduces the number of patients in the D zone by approximately 50%, increasing those in the B zone; the number of patients in the A zone remains almost unchanged.
The CVGA representation with the meals variation scenario (Figure 8) shows that the MPC2 doubles the number of patients in the A zone, increases those in the B zone and reduces the number of patients in the C and D zones; in particular, it was reduced by 73% in the D zone. glucose standard deviations are always lowered, especially during the night (p < .003). Note that during the night, the mean glucose is almost equal to the target, and the increase of the time below 70 mg/dl in the sensitivity variation scenario is negligible (p > .78). In the meal variations scenario, as reported in Table 6 , the time in target is almost 100% combined with a decrease of the time below 70 mg/dl (p < .06); a negligible increase of the mean glucose (p > .51) and the time above 180 mg/dl (p > .68) is detected in the postprandial period.
Conclusions
The new MPC controller proposed in this article is an evolution of the algorithm presented by Soru and coauthors 10 that was used during the CAT AP@home trial. 21 The new MPC incorporates clinical experience included in the collected data and also some clinical knowledge that is very critical to develop an artificial pancreas ready for long-term outpatient experiments. In silico results are very promising in terms of mean glucose, time in target, and number of patients in the critical zone of the CVGA. This algorithm, complemented with the SSM, 22 has been implemented on the a O is overall, N is night, PP is the mean relative to all postprandial periods; M is the mean of the BG (mg/dl); SD is the standard deviation of the BG (mg/dl); Tt is the percentage of time spent in euglycemic target (70-180 mg/dl); Ttt is the percentage of time spent in tight target (80-140 mg/dl); Ta is the percentage of time spent above 180 mg/dl; Tb is the percentage of time spent below 70 mg/dl; and Th is the percentage of time spent below 50 mg/dl. b p < .001. c p < .01. d p < .05.
